Xcopri

Active Ingredient(s): Cenobamate
FDA Approved: * November 21, 2019
Pharm Company: * SK LIFE SCIENCE INC
Category: Anticonvulsant

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Xcopri Overview

Cenobamate, sold under the brand name Xcopri, is for the treatment of partial-onset seizures in adults.[2][3] It was approved for medical use in the United States in November 2019[2][3][4] and placed in Schedule V in March 2020.[5] Contents 1 Pharmacology 1.1 Pharmacodynamics 2 History 3 References 4 Further reading 5 External links Pharmacology Pharmacodynamics Cenobamate is a voltage-...

Read more Xcopri Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Cenobamate

Recent Xcopri Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Cenobamate

Tablet: 100mg, 12.5mg, 150mg, 200mg, 25mg, 50mg

Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Xcopri: (4 results)

Sorted by National Drug Code

71699-050 Xcopri 50 mg Oral Tablet, Film Coated by Sk Life Science, Inc.
71699-100 Xcopri 100 mg Oral Tablet, Film Coated by Sk Life Science, Inc.
71699-150 Xcopri 150 mg Oral Tablet, Film Coated by Sk Life Science, Inc.
71699-200 Xcopri 200 mg Oral Tablet, Film Coated by Sk Life Science, Inc.

Other drugs which contain Cenobamate or a similar ingredient: (1 result)

CENOBAMATE